Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatic Artery | 2 | 2024 | 21 | 1.490 |
Why?
|
| Thrombectomy | 1 | 2024 | 73 | 0.830 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 333 | 0.800 |
Why?
|
| Liver Transplantation | 1 | 2024 | 165 | 0.760 |
Why?
|
| Embolization, Therapeutic | 2 | 2021 | 90 | 0.740 |
Why?
|
| Stents | 1 | 2024 | 372 | 0.690 |
Why?
|
| Radiography, Interventional | 2 | 2024 | 58 | 0.620 |
Why?
|
| Yttrium Radioisotopes | 1 | 2019 | 9 | 0.620 |
Why?
|
| Liver Circulation | 1 | 2019 | 21 | 0.620 |
Why?
|
| Balloon Occlusion | 1 | 2019 | 17 | 0.610 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 204 | 0.570 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 12 | 0.430 |
Why?
|
| Hospital Costs | 1 | 2014 | 73 | 0.410 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 150 | 0.400 |
Why?
|
| Ambulatory Care | 1 | 2014 | 239 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 201 | 0.360 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5471 | 0.270 |
Why?
|
| Suction | 1 | 2024 | 23 | 0.220 |
Why?
|
| Vascular Patency | 1 | 2024 | 82 | 0.220 |
Why?
|
| Time Factors | 2 | 2024 | 2989 | 0.210 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6643 | 0.200 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 179 | 0.180 |
Why?
|
| Thrombosis | 1 | 2024 | 260 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2021 | 36 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2020 | 8 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2022 | 177 | 0.170 |
Why?
|
| Enbucrilate | 1 | 2019 | 6 | 0.160 |
Why?
|
| Middle Aged | 4 | 2024 | 13084 | 0.160 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 15 | 0.160 |
Why?
|
| Heart Injuries | 1 | 2019 | 16 | 0.160 |
Why?
|
| Aged | 3 | 2024 | 10193 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 638 | 0.150 |
Why?
|
| Jaundice, Obstructive | 1 | 2018 | 6 | 0.150 |
Why?
|
| Cholelithiasis | 1 | 2018 | 12 | 0.150 |
Why?
|
| Embalming | 1 | 2018 | 7 | 0.150 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 80 | 0.140 |
Why?
|
| Radiology, Interventional | 1 | 2018 | 28 | 0.140 |
Why?
|
| Cadaver | 1 | 2018 | 95 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 222 | 0.140 |
Why?
|
| Aneurysm, False | 1 | 2018 | 43 | 0.140 |
Why?
|
| Arteries | 1 | 2018 | 93 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2019 | 172 | 0.140 |
Why?
|
| Adult | 3 | 2024 | 14151 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 139 | 0.130 |
Why?
|
| Humans | 9 | 2024 | 52469 | 0.120 |
Why?
|
| Male | 5 | 2024 | 26794 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1025 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 328 | 0.120 |
Why?
|
| Female | 4 | 2024 | 28192 | 0.110 |
Why?
|
| Direct Service Costs | 1 | 2014 | 5 | 0.110 |
Why?
|
| Disposable Equipment | 1 | 2014 | 4 | 0.110 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2014 | 11 | 0.110 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 20 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 39 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 269 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 3413 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 3945 | 0.080 |
Why?
|
| Arkansas | 1 | 2014 | 2024 | 0.070 |
Why?
|
| Steroids | 1 | 2022 | 60 | 0.050 |
Why?
|
| Mediastinum | 1 | 2021 | 21 | 0.040 |
Why?
|
| Vincristine | 1 | 2021 | 88 | 0.040 |
Why?
|
| Axilla | 1 | 2021 | 92 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 102 | 0.040 |
Why?
|
| Pelvis | 1 | 2021 | 67 | 0.040 |
Why?
|
| Connecticut | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 172 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 123 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 241 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 55 | 0.040 |
Why?
|
| Angioplasty, Balloon | 1 | 2019 | 70 | 0.040 |
Why?
|
| Catheterization | 1 | 2019 | 96 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2018 | 33 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 119 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 588 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2670 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2022 | 2875 | 0.030 |
Why?
|